<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000410751"><TermName>Pegasys</TermName><TermPronunciation>(PEH-guh-sis)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat hepatitis C infections. It is also being studied in the treatment and prevention of cancer. It is a cytokine that is modified in the laboratory. It is a type of biological response modifier. Also called peginterferon alfa-2a.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713142" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Pegasys&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713141" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Pegasys&quot;" language="es" id="_4"/><SpanishTermName>Pegasys</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento usado para tratar la infección por hepatitis C. Asimismo, está en estudio para el tratamiento y la prevención de cáncer. Es una citocina modificada en el laboratorio. Es un tipo de modificador de la respuesta biológica. También se llama peginterferón a-2a.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2005-03-24</DateFirstPublished><DateLastModified>2007-04-12</DateLastModified></GlossaryTerm>
